FDA extends review of Ascendis Pharma's hormone disorder therapy-June 2024-www.financetom.com

FDA extends review of Ascendis Pharma's hormone disorder therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA extends review of Ascendis Pharma's hormone disorder therapy

May 14, 2024 11:53 AM

May 14 (Reuters) -

The U.S. Food & Drug Administration has extended its review

of Ascendis Pharma's ( ASND ) therapy to treat adult patients

with a hormone disorder, the company said on Tuesday.

The FDA is now set to make its decision known by Aug. 14,

compared to its previous action date set for May 14.

Previous page： Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027 Next page： Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027

Sep 13, 2024

11:09 AM EDT, 09/12/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) Moderna ( MRNA ) shares fell more than 18% in recent Thursday trading after the company said it is reducing its annual R&D expense by about $1.1 billion starting in 2027 in light of recent commercial challenges. The company now...

Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing

Sep 13, 2024

11:08 AM EDT, 09/12/2024 (MT Newswires) -- Dennis H Nelson, Director, President & CEO, on September 10, 2024, sold 20,453 shares in Buckle (BKE) for $854,496. Following the Form 4 filing with the SEC, Nelson has control over a total of 2,310,552 shares of the company, with 324,000 shares held directly and 1,986,552 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885245/000088524524000087/xslF345X05/wk-form4_1726153070.xml Price: 41.56,...

--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro

Sep 13, 2024

11:09 AM EDT, 09/12/2024 (MT Newswires) -- Price: 222.76, Change: +0.10, Percent Change: +0.04 ...

Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall

Sep 13, 2024

11:13 AM EDT, 09/12/2024 (MT Newswires) -- Oncternal Therapeutics' ( ONCT ) shares sank 58% in recent Thursday trading after the company said it has decided to discontinue its clinical studies and explore strategic alternatives. The company also said it will discontinue all product development activities, lay off some staff, and implement other cost-cutting measures while exploring alternatives, which may...